CStone Pharmaceuticals (HK:2616)
:2616
Top Page
CStone Pharmaceuticals
(2616)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$5.00
▼(-6.37% Downside)
Action:ReiteratedDate:11/05/25
CStone Pharmaceuticals faces significant financial and operational challenges, with declining revenue and persistent losses being the most impactful factors. The technical indicators suggest bearish momentum, and the negative P/E ratio highlights valuation concerns. The absence of earnings call data and corporate events limits additional insights.
Positive Factors
Balance Sheet Strength
A moderate debt load combined with a healthy equity ratio gives CStone structural financial flexibility. This capital base supports ongoing R&D and commercial efforts, reduces near-term refinancing pressure, and provides a buffer while the company works toward operational break-even.
Negative Factors
Revenue Decline & Losses
Sustained revenue decline and ongoing losses undermine long-term sustainability. Persistent top-line contraction limits reinvestment in R&D and commercialization, increases reliance on external funding, and raises execution risk until revenue growth and profitability can be restored.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
A moderate debt load combined with a healthy equity ratio gives CStone structural financial flexibility. This capital base supports ongoing R&D and commercial efforts, reduces near-term refinancing pressure, and provides a buffer while the company works toward operational break-even.
Read all positive factors
CStone Pharmaceuticals (2616) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$13.59B
Dividend YieldN/A
Average Volume (3M)19.75M
Price to Earnings (P/E)―
Beta (1Y)1.23
Revenue Growth-55.64%
EPS Growth-158.67%
CountryHK
Employees135
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.14
Shares Outstanding1,476,015,400
10 Day Avg. Volume13,736,900
30 Day Avg. Volume19,747,038
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)7.58
Price to Sales (P/S)6.77
P/FCF Ratio-8.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$9.87Price Target Upside84.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.16
Revenue Forecast (FY)HK$448.42M
CStone Pharmaceuticals Business Overview & Revenue Model
Company Description
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a mono...
How the Company Makes Money
CStone Pharmaceuticals generates revenue primarily through the commercialization of its pharmaceutical products, including sales of approved therapies. The company also engages in collaborative partnerships and licensing agreements with other phar...
CStone Pharmaceuticals Financial Statement Overview
Summary
Income Statement
40
Negative
Balance Sheet
55
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 177.77M | 407.20M | 463.84M | 481.36M | 243.72M | 1.04B |
| Gross Profit | 21.73M | 240.15M | 304.30M | 278.38M | 136.89M | 797.41M |
| EBITDA | -216.63M | -76.43M | -297.23M | -849.66M | -1.90B | -1.20B |
| Net Income | -242.00M | -91.21M | -367.23M | -902.68M | -1.92B | -1.22B |
Balance Sheet | ||||||
| Total Assets | 1.19B | 1.39B | 1.66B | 1.64B | 2.27B | 3.76B |
| Cash, Cash Equivalents and Short-Term Investments | 690.10M | 672.94M | 1.05B | 1.04B | 1.73B | 3.39B |
| Total Debt | 391.37M | 355.97M | 363.45M | 286.29M | 174.20M | 83.86M |
| Total Liabilities | 876.86M | 1.03B | 1.21B | 1.19B | 1.06B | 808.29M |
| Stockholders Equity | 315.04M | 363.87M | 456.83M | 449.33M | 1.21B | 2.95B |
Cash Flow | ||||||
| Free Cash Flow | -156.05M | -343.18M | -653.89M | -714.29M | -1.63B | -579.52M |
| Operating Cash Flow | -156.05M | -343.18M | -588.84M | -612.47M | -1.48B | -508.07M |
| Investing Cash Flow | -149.95M | -247.68M | 619.61M | 365.12M | -826.55M | 1.18B |
| Financing Cash Flow | 22.58M | -12.90M | 388.36M | 28.47M | 92.30M | 1.39B |
CStone Pharmaceuticals Technical Analysis
Positive
5.34
Price Trends
6.39
Positive
6.07
Positive
6.73
Positive
Market Momentum
0.68
Negative
76.01
Negative
93.28
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2616, the sentiment is Positive. The current price of 5.34 is below the 20-day moving average (MA) of 7.39, below the 50-day MA of 6.39, and below the 200-day MA of 6.73, indicating a bullish trend. The MACD of 0.68 indicates Negative momentum. The RSI at 76.01 is Negative, neither overbought nor oversold. The STOCH value of 93.28 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2616.
CStone Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | HK$9.02B | 135.64 | 11.21% | ― | 23.37% | ― | |
53 Neutral | HK$8.81B | -76.25 | -6.26% | ― | 206.58% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$12.80B | 5.89 | 18.28% | ― | 59.70% | 239.97% | |
44 Neutral | HK$1.96B | -3.21 | -137.11% | ― | ― | -18.99% | |
42 Neutral | HK$13.59B | -15.44 | -64.19% | ― | -55.64% | -158.67% |
* Healthcare Sector Average
HK:2616
CStone Pharmaceuticals
9.35
7.13
321.17%
HK:9966
Alphamab Oncology
9.04
3.00
49.67%
HK:2142
HBM Holdings Ltd.
14.47
8.57
145.25%
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
4.10
-2.71
-39.79%
HK:2256
Abbisko Cayman Limited
13.26
6.90
108.49%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
6.98
-1.51
-17.79%
CStone Pharmaceuticals Corporate Events
CStone Pharmaceuticals Sets March Board Meeting and Investor Call to Detail 2025 Results and Oncology Pipeline Progress
Feb 2, 2026
CStone Pharmaceuticals has scheduled a board meeting for March 26, 2026 to review and approve its audited annual results for the year ended December 31, 2025, after which it will release the results and issue a voluntary announcement. The company ...
CStone CEO Boosts Stake to 4.87% in Sign of Long-Term Confidence
Jan 27, 2026
CStone Pharmaceuticals announced that its CEO, president of research and development, and executive director, Dr. Jianxin Yang, has further increased his personal stake in the company by purchasing 976,000 shares on the open market between Novembe...
CStone Pharmaceuticals Grants New Share Options and RSUs, Seeks Shareholder Nod for Director Awards
Jan 23, 2026
CStone Pharmaceuticals’ board has granted 15,715,500 share options to 96 grantees and 8,055,000 restricted share units (RSUs) to 88 grantees under its post-IPO equity incentive schemes, with allocations covering one director and multiple emp...
CStone Pharmaceuticals Reshapes Board With New Independent Director Appointment
Jan 21, 2026
CStone Pharmaceuticals has appointed veteran accounting and assurance professional Catherine Yen as an independent non-executive director, effective 21 January 2026, and named her chairperson of the compensation committee as well as a member of th...
CStone Pharmaceuticals Sets Out Board and Committee Structure
Jan 21, 2026
CStone Pharmaceuticals has announced the current composition of its board of directors and detailed the allocation of roles across its five board committees. The company confirmed Dr. Jianxin Yang as executive director and chief executive officer,...
CStone Pharmaceuticals’ GAVRETO® Gains Inclusion in China’s National Reimbursement Drug List
Dec 8, 2025
CStone Pharmaceuticals announced the inclusion of GAVRETO® (pralsetinib) in China’s National Reimbursement Drug List (NRDL), effective January 1, 2026. This inclusion marks a significant milestone for CStone, enhancing its market presen...
CStone’s Sugemalimab Gains European Approval for Broader NSCLC Treatment
Nov 25, 2025
CStone Pharmaceuticals announced that the European Commission has approved sugemalimab as a monotherapy for adult patients with unresectable stage III non-small cell lung cancer (NSCLC) with specific genetic profiles. This approval expands sugemal...
CStone Pharmaceuticals Unveils CS2015 at ACAAI 2025
Nov 7, 2025
CStone Pharmaceuticals has announced the international debut of its bispecific antibody, CS2015, at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology (ACAAI). This marks the first presentation of CS2015 a...
CStone Pharmaceuticals Advances CS2009 Clinical Trials with NMPA Approval
Nov 4, 2025
CStone Pharmaceuticals announced the approval of their Investigational New Drug application by the China National Medical Products Administration for Phase II clinical trials of CS2009, a tri-specific antibody targeting PD-1, VEGF, and CTLA-4, for...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.